Clinical Trial Update: A Study of CD19 Redirected Autologous T Cells for CD19 Positive Systemic Lupus Erythematosus (SLE) [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating CD19-directed autologous T cells for CD19-positive systemic lupus erythematosus (SLE) is being conducted; current status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• CD19 Redirected Autologous T Cells

Snippet

Sponsor: Shanghai GeneChem Co., Ltd. | Conditions: Systemic Lupus Erythematosus (SLE) | Phase 1 | Status: UNKNOWN